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appear to be little likelihood that the small quantities of
lanthanum absorbed with therapeutic doses of lanthanum
carbonate will lead to lysosomal overload and toxicity.
Extensive preclinical and clinical safety testing supports this
conclusion.
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Response to ‘Enlightenment
on liver lanthanum exposure’
Kidney International (2006) 70, 1373. doi:10.1038/sj.ki.5001675
In a letter to the editor, Damment1 from Shire Pharma-
ceuticals has questioned the interpretation of the results
from our recently published study in this journal.2 We
looked at the tissue accumulation of lanthanum in kidney,
bone, and liver from normal and uremic lanthanum-
treated rats. In Damment’s letter, he suggests that the only
appropriate comparison is the one between the lantha-
num-treated normal and lanthanum-treated uremic rats.
When looking at tissue accumulation, the appropriate
control for lanthanum-treated uremic rats is untreated
uremic rats. When we made this comparison, we demon-
strated a progressive accumulation of lanthanum in liver
over the entire course of the study. We also observed that
uremia enhances the accumulation of lanthanum as has
been shown by other investigators.3,4 In his letter,
Damment includes a graph showing that lanthanum
accumulation reaches steady-state conditions in longer
term studies. This study, however, was not performed in
uremic rats, but in normal animals. As with Damment’s
study, we also saw that lanthanum accumulation in liver
begin to plateau in lanthanum-treated normal rats.2
Lanthanum, however, will not be prescribed to normal
individuals; thus, these results have no relevance for
hemodialysis patients. On the other hand, Bervoets et al.3
showed significantly greater gastrointestinal absorption of
lanthanum in renal failure. This explains why we see a
greater and progressive accumulation of lanthanum in the
uremic state. Initial concern for lanthanum use had
centered around its potential effects on bone and brain,
as these were the tissues adversely affected by aluminum-
containing phosphate binders.5 We state in our paper that
lanthanum likely has no effect on either of these tissues or
for that matter, kidney. Given the experience with
aluminum-containing phosphate binders, we must be
certain that treatments designed to benefit our patients
will not, in fact, harm them. The jury is still out.
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Downloadable computer models
for maintenance but not acute
renal replacement therapy
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To the Editor: The hemodialysis clearance calculators
developed by Walther et al.1 are a commendable initiative.
However, we wish to draw attention to their limitations for
modelling acute renal replacement therapy in the intensive
care unit. Like Michael’s equation, Dr Addis’ hemodialyzer
clearance (Kd) calculator assumes a fixed configuration for
blood flow (QB) and dialysate flow (QD) within the
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Figure 1 | Long-term liver lanthanum exposure. Liver lanthanum
concentrations in rats treated for 1 day, or 4, 12, 26, or 78 weeks with
1500–2000 mg/kg lanthanum carbonate, 13–17 times the human
dose of 3 g/day of elemental lanthanum. Values are the median and
25th/75th percentiles, n¼ 4–12 rats per time point. Data on file at
Shire Pharmaceuticals Inc., in preparation for publication.
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